Brief: Roivant Sciences Q3 EPS USD 0.23
10/02/2025 12:00
Feb 10 (Reuters) - Roivant Sciences Q3 operating expenses USD 283.399 million. * Q3 income from operations USD -274.381 million vs. IBES estimate USD -275.2 million * Q3 net income USD 118.075 million
Recent news on Roivant Sciences
See all newsU.S. STOCKS ON THE MOVE-Thermo Fisher, CME, Capital One, Northern Trust
Roivant rises as drug succeeds in two late-stage trials for eye disease
Immunovant falls after lupus drug setback
Brief: Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple